Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential Commercialization SOUTH SAN ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...

Q4 2024 Earnings Call Transcript February 11, 2025 Royalty Pharma plc misses on earnings expectations. Reported EPS is ...

Cytokinetics (CYTK) announced the appointment of Robert Landry to its Board of Directors. Mr. Landry brings over three decades of financial and ...

Fintel reports that on February 7, 2025, Citigroup initiated coverage of Cytokinetics (NasdaqGS:CYTK) with a Buy ...

Cytokinetics (CYTK) was initiated by Citi analysts with a Buy rating, citing potential FDA approval for its lead asset ...

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the ...

BofA notes that Cytokinetics (CYTK) shares are under pressure this morning after rival Bristol Myers (BMY) confirmed European regulators had ...

Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) – B. Riley boosted their FY2024 earnings per share estimates for Cytokinetics in a note issued to investors on Wednesday, February 5th.

The next phase of Kilroy's big Oyster Point project is seeing interest from tech and financial services as well as biotech, ...

Cytokinetics' flagship program, aficamten, is a cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy (HCM), a condition characterized by thickening of the heart muscle.